BullFrog AI Holdings (BFRG) Cash from Financing Activities (2022 - 2025)
BullFrog AI Holdings' (BFRG) quarterly Cash from Financing Activities came in at $1.4 million in Q4 2025, down 44.19% on a YoY basis from $2.5 million in Q4 2024, and up 120.74% quarter-over-quarter from $624249.0 in Q3 2025.
Analysis
BullFrog AI Holdings (BFRG) Cash from Financing Activities (2022 - 2025) Analysis & Trends
BullFrog AI Holdings (BFRG) has reported Cash from Financing Activities for 4 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 44.19% year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2025 stood at $2.4 million (down 71.8% YoY), and the FY2025 full-year result was $2.4 million, down 71.8% from the prior year.
- Cash from Financing Activities rose to $1.4 million in Q4 2025 per BFRG's latest filing, from $624249.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $7.7 million in Q1 2023 and bottomed at -$213290.0 in Q4 2023.
- Historically, Cash from Financing Activities has averaged $1.3 million across 4 years, with a median of $186375.0 in 2025.
- The widest YoY moves for Cash from Financing Activities: up 32418.68% in 2023, down 487.1% in 2023.
- Over 4 years, Cash from Financing Activities stood at $55100.0 in 2022, then slumped by 487.1% to -$213290.0 in 2023, then soared by 1257.59% to $2.5 million in 2024, then slumped by 44.19% to $1.4 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.4 million, $624249.0, and $208680.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 27.18 Mn |
| 10 | BullFrog AI Holdings | 9.27 Mn | 2.35 Mn | 106,899.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.38 Mn |
| Sep 30, 2025 | 624,249.00 |
| Jun 30, 2025 | 208,680.00 |
| Mar 31, 2025 | 164,070.00 |
| Dec 31, 2024 | 2.47 Mn |
| Sep 30, 2024 | -169,035.00 |
| Jun 30, 2024 | -166,114.00 |
| Mar 31, 2024 | 6.29 Mn |
| Dec 31, 2023 | -213,290.00 |
| Sep 30, 2023 | -209,761.00 |
| Jun 30, 2023 | 1.27 Mn |
| Mar 31, 2023 | 7.72 Mn |
| Dec 31, 2022 | 55,100.00 |
| Sep 30, 2022 | 63,000.00 |
| Jun 30, 2022 | 825,440.00 |
| Mar 31, 2022 | 23,750.00 |